SCHEMBL2835309

SCHEMBL2835309

C=C(C)COC(=O)c1cc(F)c(F)c(OC)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.38
TSHR P16473 2/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CRBN Q96SW2 2/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 2/20 0.33
NPC1 O15118 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829961 0.83 KMT2A (0.42) GAATSHRUSP2LMNAMAPT
SCHEMBL2835446 0.82 TSHR (0.44) TSHRLMNAMAPTHPGDNPSR1
Acetic Acid SCHEMBL28937184 0.81 TSHR (0.41) GAATSHRLMNAMAPTHPGD
SCHEMBL28785157 0.81 GAA (0.37) GAATSHRUSP2LMNAMAPT
SCHEMBL2834707 0.81 KMT2A (0.51) GAATSHRKMT2APOLBMEN1
SCHEMBL2831392 0.81 KMT2A (0.47) GAATSHRLMNAKMT2AMEN1
SCHEMBL2834377 0.80 CYP3A4 (0.47) TSHRLMNAMAPTHPGDSMN1; SMN2
SCHEMBL2838554 0.79 NPC1 (0.36) GAATSHRUSP2LMNAMAPT
SCHEMBL2832574 0.79 ALDH1A1 (0.47) TSHRLMNAMAPTNPSR1KMT2A
SCHEMBL2838473 0.79 MMP1 (0.38) TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 GAA 990/4885TSHR 3459/4885USP2 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.